Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-baesd chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells and who do not have EGFR mutant or ALK-positive mutations.
This is written in the approval document as:
Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Atezolizumab |